About 100 reports

  • Key market highlights

Oral iron drugs have been linked with adverse gastrointestinal side effects and require multiple daily doses.

  • Endocrine Disease
  • Allergan plc
  • AMAG Pharmaceuticals, Inc.
  • Daiichi Sankyo Company
  • Galenica Group
  • SANOFI

IT IS INVOLVED IN DISCOVERING, DEVELOPING, MANUFACTURING, AND COMMERCIALIZING PRESCRIPTION MEDICINES FOR THE TREATMENT OF ONCOLOGY, CARDIOVASCULAR AND METABOLIC, RESPIRATORY, INFECTION, GASTROINTESTINAL, AND NEUROSCIENCE DISEASES GLOBALLY.

  • Endocrine Disease
  • World
  • AstraZeneca PLC
  • Horizon Pharma plc
  • Sanofi S.A.
  • 2.10 Co-morbidities and Complications

Gastrointestinal events such as nausea and diarrhea occurred most frequently.

  • Endocrine Disease
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Sanofi S.A.
  • 1.1 I.V. Iron Application Areas
  • 3.1 Growth Drivers

Hemodialysis patients keep on loosing iron incessantly through gastrointestinal bleeding, blood drawing, and mostly from the hemodialysis treatment itself.

  • Endocrine Disease
  • Actavis plc
  • AMAG Pharmaceuticals, Inc.
  • Galenica Group
  • Vifor Pharma
  • Dipep

Gastrointestinal events such as nausea and diarrhea occurred most frequently.

  • Endocrine Disease
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

GASTROINTESTINAL ADVERSE EFFECTS WERE MORE COMMON IN THE VICTOZA TREATMENT ARM COMPARED TO BYDUREON.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • T1DM Therapeutics Market, Global, All Pipeline Products, Discovery Phase, 2015

It manifests as dysfunction of one or more organ systems including the cardiovascular, gastrointestinal, genitourinal, sudomotor and ocular systems.

  • Endocrine Disease
  • World
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group

Gastrointestinal events such as nausea and diarrhea occurred most frequently.

  • Endocrine Disease
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

CLINICAL TRIALS HAVE FOUND FOSRENOL TREATMENT TO BE GENERALLY WELL TOLERATED, WITH ADVERSE EVENTS TYPICALLY BEING GASTROINTESTINAL.

  • Endocrine Disease
  • Forecast
  • Amgen Inc.
  • Keryx Biopharmaceuticals, Inc.
  • OPKO Health, Inc.

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Sanofi S.A.

FERRIC CITRATE BINDS TO PHOSPHATE IN THE GASTROINTESTINAL TRACT AND DECREASES SERUM PHOSPHORUS CONCENTRATION THROUGH INHIBITING PHOSPHATE ABSORPTION INTO THE BODY.

  • Endocrine Disease
  • World
  • AbbVie Inc.
  • Novartis AG
  • OPKO Health, Inc.
  • Investigators Information
  • Iron Deficiency Anemia Therapeutics Clinical Trials Market, Global, Clinical Trials by AMAG...

February 2014", GlobalData inferred that gastrointestinal adverse events (AEs) were observed.

  • Endocrine Disease
  • AMAG Pharmaceuticals, Inc.
  • Daiichi Sankyo Company
  • Galenica Group
  • Rockwell Medical, Inc.

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • PEPTIDE THERAPEUTICS IN METABOLIC DISORDERS: TECHNOLOGY PLATFORMS
  • 1. CONJU33

THIS IS DONE TO DECREASE THE PROBABILITY OF GASTROINTESTINAL SYMPTOMS.

  • Endocrine Disease
  • Glucagon Like Peptide 1 Receptor Activator
  • United States
  • LipimetiX Development LLC
  • Novartis AG

Systemic amyloidosis (AL amyloidosis or just primary amyloidosis) is a medical condition which involves the mesenchymal tissue, the tongue, heart, gastrointestinal tract, and skin.

  • Endocrine Disease
  • Pathology
  • Asia
  • Forecast

PRIOR TO THAT, SHE WAS A PRODUCT DEVELOPMENT ENGINEER AT AN NIH-FUNDED SBIR FIRM, WHERE SHE WORKED ON GASTROINTESTINAL BIOPSY AND ORTHOPEDIC DEVICES.

  • Endocrine Disease
  • Europe
  • B. Braun Melsungen AG
  • ConvaTec Inc.
  • Covidien plc

Most commonly reported adverse effects were gastrointestinal related and they were consistent with previous studies.

  • Endocrine Disease
  • Insulin
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited

The gastrointestinal therapeutics market recorded ## partnership deals and six licensing deals worth USD##. ## billion in Q## 2016.

  • Endocrine Disease
  • Pharmaceutical
  • World
  • Deals & Alliance
  • AstraZeneca PLC
  • 5.6.1 PHARMACEUTICALS & HEALTHCARE, GLOBAL, METABOLIC DISORDERS DEALS, 2016 BY QUARTER

FIGURE ## SHOWS THE TOTAL NUMBER OF GASTROINTESTINAL THERAPY DEALS WITH DISCLOSED DEAL VALUES.

  • Endocrine Disease
  • Hospital
  • World
  • Company
  • Deals & Alliance
  • DRUGS TO INHIBIT ABHD6 FOR GASTROINTESTINAL AND METABOLIC DISORDERS - DRUG PROFILE
  • ASSESSMENT BY MOLECULE TYPE
  • Diabetes
  • Endocrine Disease
  • World
  • Product Initiative
  • PhaseBio Pharmaceuticals, Inc.

Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Immunology and Undisclosed which include indications Obesity, Dyslipidemia, Hyperlipidemia, Inflammation, Non-Alcoholic Steatohepatitis (NASH), Type ## Diabetes and Unspecified.

  • Endocrine Disease
  • Oleochemicals
  • United States
  • World
  • Product Initiative
  • Secondary Hyperparathyroidism - Pipeline by Shire Plc, H2 2017

It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases.

  • Endocrine Disease
  • Therapy
  • United States
  • World
  • Product Initiative
  • HYPERINSULINEMIA - PIPELINE BY EIGER BIOPHARMACEUTICALS INC, H1 2017
  • EXENDIN-(9-39) - DRUG PROFILE

This gastrointestinal hormone, GLP-## is released after meal.

  • Endocrine Disease
  • United States
  • World
  • Product Initiative
  • XOMA Corporation

HOWEVER, MANY SIDE EFFECTS SUCH AS HYPOGLYCEMIA, LACTIC ACID INTOXICATION AND GASTROINTESTINAL UPSET, ETC.

  • Diabetes
  • Endocrine Disease
  • Insulin
  • Spice
  • World
  • Synlogic Inc, Deals By Therapy Area, 2011 to YTD 2017

Synlogic Inc Pharmaceuticals & Healthcare - Deals and Alliances Profile August 2017 Report Code: GDPH##D Published: Synlogic Inc (Synlogic), formerly TMC Therapeutics Inc is a drug development company that develops drug candidates for the treatment of rare, genetic metabolic diseases.

  • Endocrine Disease
  • United States
  • Company
  • M&A
  • Synlogic, Inc.
  • 1.2 Types
  • 1.1 Introduction

It is beneficial in stabilizing gastrointestinal problems, as well as neurological symptoms.

  • Endocrine Disease
  • Pharmaceutical
  • World
  • Forecast
  • Prothena Corporation plc
  • HYPOPARATHYROIDISM - PIPELINE BY SHIRE PLC, H1 2017
  • HYPOPARATHYROIDISM - PIPELINE BY PHARIS BIOTEC GMBH, H1 2017

It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases.

  • Endocrine Disease
  • Therapy
  • United States
  • World
  • NPS Pharmaceuticals, Inc.